Clinical Trial Detail

NCT ID NCT04050280
Title CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Maryland, Baltimore
Indications

acute myeloid leukemia

Therapies

Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin

Gemtuzumab ozogamicin

Cladribine + Cytarabine + Filgrastim

Age Groups: senior adult

No variant requirements are available.